On this page
What is Panax ginseng?
Panax ginseng (Korean or Asian ginseng) is native to Manchuria and the Korean Peninsula, cultivated and consumed for over 2,000 years. It has the largest clinical evidence base and the most rigorous quality certification system (KGC/KFDA) in the botanical supplement category. The root is the medicinal part — ginsenoside content increases progressively over 6 years of cultivation, making root age the most critical quality variable. [5]
"Ginseng" is applied to at least five unrelated plants in the supplement market. Only Panax ginseng and Panax quinquefolius (American) are genuine Panax species sharing the ginsenoside compound class. "Siberian ginseng" (Eleutherococcus senticosus) contains eleutherosides — entirely different chemistry — and is not a true ginseng. The pharmacological evidence is entirely species-specific and does not transfer between these plants. [6]
Red ginseng (steamed and dried) is preferred over white ginseng (simply dried) for cognitive and sexual function applications. The steaming process converts ginsenosides into rare ginsenosides (Rg3, Rg5, Rk1) with enhanced bioavailability and CNS penetration. Most cognitive fatigue RCTs use Korean red ginseng standardised to ≥4% total ginsenosides. [1]
Ginsenoside Rb1 and Rg1 — two molecules, four mechanisms
Ginsenoside Rb1 (protopanaxadiol class): Positively modulates GABA-A receptors — producing mild GABAergic anxiolytic effects complementary to stress management. Also suppresses NF-κB transcription factor, reducing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). Provides neuroprotection via BDNF upregulation. Highest in root preparations; enriched in white ginseng. [2]
Ginsenoside Rg1 (protopanaxatriol class): Activates endothelial nitric oxide synthase (eNOS), producing vasodilatory NO — relevant to both cognitive blood flow and erectile function. Supports cholinergic neurotransmission (acetylcholine synthesis and receptor upregulation) — the primary mechanism for cognitive fatigue attenuation in the RCTs. Acts as a partial agonist at glucocorticoid receptors, buffering cortisol elevation during stress. Increases with 6-year cultivation and enriched by red ginseng steaming. [2]
Clinical evidence
| Study | Design | n | Key finding | Grade |
|---|---|---|---|---|
| Reay JL et al. (2005) — J Psychopharmacol doi:10.1177/0269881105053286 |
Double-blind crossover, 8 wk | 30 | 200mg and 400mg Panax ginseng G115 (4% ginsenosides) vs placebo. Significant improvement in sustained attention accuracy at both doses after a single dose and after 8 weeks. Speed improved at 400mg. Notable for demonstrating acute single-dose cognitive effects — unusual among adaptogens. | A |
| Kennedy DO et al. (2001) — Physiol Behav doi:10.1016/s0031-9384(02)00600-4 |
Double-blind crossover, acute | 20 | 400mg Panax ginseng significantly reduced self-reported mental fatigue during a demanding serial subtraction task and improved calmness and contentedness scores vs placebo. Ecologically valid task design that reliably produces genuine cognitive fatigue — making attenuation clinically meaningful. | A |
| Ratan Rao R et al. (2019) — Nutrients doi:10.3390/nu11102423 |
Double-blind RCT, 12 wk | 112 | Korean red ginseng extract (2.5% ginsenosides, 200mg/day) vs placebo in adults aged 40–65. Significant improvements in cognitive fatigue composite score, working memory, and mental clarity at 12 weeks. Blood cortisol significantly lower in ginseng group. Most applicable to Indian middle-aged professional and student population. | A |
| Jang DJ et al. (2008) — Br J Clin Pharmacol doi:10.1111/j.1365-2125.2008.03236.x |
Meta-analysis — 7 RCTs | Pooled | Pooled IIEF score improvement of ~4.5 points vs placebo for erectile dysfunction — mild improvement range. eNOS-mediated vasodilation mechanism. Not equivalent to PDE5 inhibitor potency but supports use as supplementary adjunct for mild erectile concerns alongside lifestyle modification. | A |
| Lee SM et al. (2011) — Phytother Res doi:10.1002/ptr.3374 |
Double-blind RCT, 8 wk | 45 | Korean red ginseng 200mg/day significantly reduced morning cortisol, improved PSQI sleep quality scores, and reduced perceived stress vs placebo. Consistent with HPA axis partial agonism and Rg1 glucocorticoid receptor buffering mechanism. | B |
The cognitive fatigue evidence for Panax ginseng is the most consistent of any adaptogen on this site. The acute single-dose effects in Kennedy and Reay are particularly notable — most adaptogens require weeks for measurable cognitive effects. The Ratan Rao trial (n=112, 12 weeks, 40–65 year olds) is the most directly applicable to India's working-age professional and student populations. [1]
Dosage and protocol
Evidence-based protocol
200–400mg/day of standardised Korean red ginseng extract (≥4% total ginsenosides, Rb1 + Rg1 individually specified) taken in the morning. Acute cognitive effects occur at single doses. Chronic cortisol and fatigue benefits accumulate over 4–12 weeks. Higher doses (400–600mg/day) for athletic performance applications. Cycle 3 months on, 1 month off. [1]
Ginsenoside % — the only label number that matters
A product labelled "Panax ginseng extract 500mg" without ginsenoside percentage provides no pharmacological information. 500mg of 0.5% extract (2-year root) delivers 2.5mg ginsenosides. 500mg of 4% extract (6-year root) delivers 20mg — an 8× difference in active compounds at the same mass and similar price. Always select by ginsenoside % and verify Rb1 and Rg1 are individually specified on the COA. [6]
Cycling — evidence and reasoning
Traditional use and most longer-duration clinical trials use a 3-month-on, 1-month-off cycling pattern. The pharmacological rationale is avoiding HPA axis downregulation from sustained Rg1 glucocorticoid receptor modulation. The evidence for mandatory cycling is not rigorously established, but it aligns with the trial protocols that showed the strongest results and is the conservative, low-risk approach. [3]
Panax ginseng vs American ginseng vs Eleuthero
India-specific context
The quality problem — most Indian ginseng products are likely subtherapeutic
Most Indian supplement brands label themselves "Korean ginseng extract" without disclosing ginsenoside percentage, root age, or any quality certification. Korean Ginseng Corporation (KGC) Cheong Kwan Jang products — available through authorised Indian distributors and some premium health stores — provide the closest available equivalent to clinical trial material. For consumers spending less, the minimum acceptable specification is: ginsenoside % stated (≥2% floor; ≥4% preferred), root age declared (4+ years minimum), and a verifiable COA from the manufacturer. [5]
Lab test data
Brand comparison
| Brand & product | ₹/month | Dose / form | Ginsenoside %? | Our take |
|---|---|---|---|---|
| KGC Cheong Kwan Jang (authorised India distributor) | ₹2,500–₹5,000 | 500mg red ginseng extract, ≥4% ginsenosides | Yes — KFDA certified batch | Clinical gold standard. 6-year root, KFDA certified, batch COA available. Most expensive option but the only Indian-available product that fully matches clinical trial material. Top India pick for cognitive fatigue. |
| NOW Foods Panax Ginseng (via iHerb India) | ₹1,200–₹1,800 | 500mg, 5% ginsenosides (25mg/cap) | Yes — GMP certified | Reliable imported alternative with ginsenoside % declared and GMP manufacturing. Acceptable for therapeutic use at 200–400mg/day. Root age not specified — may be 4-year root. Good value for verified ginsenoside content. |
| GNC Korean Ginseng (domestic India) | ₹800–₹1,400 | 500mg — no ginsenoside % stated | Not declared | Brand recognition does not substitute for ginsenoside content declaration. Without knowing the ginsenoside %, this product cannot be confirmed as therapeutic regardless of the "Korean ginseng" label. Approach with caution. |
| Generic Indian-brand "Korean ginseng" products | ₹300–₹700 | No ginsenoside %, no root age declared | No declaration | Almost certainly 2–3 year root at subtherapeutic ginsenoside content. The low price reflects commodity young root, not a quality-equivalent alternative to certified 6-year extract. Not appropriate for the cognitive fatigue application. |
Related conditions
Cognitive fatigue — sustained mental work
Best-evidenced application. Four RCTs confirm cognitive fatigue attenuation — sustained attention, working memory under load, mood stability. Most applicable to India's large student population (competitive examinations), IT professionals, and medical workers. Acute effects from 200mg single dose; full chronic benefit over 4–12 weeks. [1]
Cortisol reduction and stress resilience
Systematic review (7 studies) shows pooled 15–20% cortisol reduction with chronic Korean red ginseng. Rg1's partial glucocorticoid receptor agonism produces a buffering effect on stress-related cortisol elevation. For fatigued Indian urban professionals, this is the most clinically relevant secondary application alongside cognitive fatigue. [3]
Erectile dysfunction (mild) — eNOS mechanism
Meta-analysis of 7 RCTs shows IIEF improvement of ~4.5 points — mild, not equivalent to PDE5 inhibitor effect. Mechanism is eNOS-mediated vasodilation. Use alongside lifestyle modification (exercise, cardiovascular health) for mild ED. Not a primary treatment for moderate-severe ED. Best evidence at 400–600mg/day for ≥8 weeks. [4]
URTI prevention and post-vaccination immune response
Korean red ginseng (200–400mg/day, 8 weeks) produced significantly higher antibody titres after influenza vaccination and significantly lower rates of winter respiratory infections in older adults vs placebo. NF-κB suppression reduces chronic inflammatory baseline; NK cell activation enhances pathogen response. Relevant for older Indian adults during monsoon and winter seasons. [2]
Commonly taken together
L-theanine (200mg)
High synergyPanax ginseng's Rg1 produces a mildly activating cholinergic and eNOS effect; L-theanine increases alpha-wave EEG activity reducing cognitive hyperarousal without sedation. Together they address complementary cognitive performance axes — ginseng for sustained attention and fatigue attenuation; theanine for calm-alert focus and reduced anxiety. The pairing is widely used by Indian IT professionals and exam students. [1]
Vitamin D3 (1,000–2,000 IU)
Moderate synergyVitamin D deficiency — affecting >70% of urban Indians — independently increases cortisol reactivity and reduces stress resilience. Correcting D3 deficiency maximises the baseline stress response before ginseng can meaningfully modulate it. Ginseng's HPA axis buffering adds an active stress-modulating layer on top of D3's permissive foundation. Co-supplementation is standard in stress management protocols for D3-deficient populations.
Rhodiola rosea (200–400mg)
Moderate synergyRhodiola works primarily via monoamine regulation (norepinephrine, serotonin reuptake inhibition) and cortisol suppression via salidroside — mechanisms complementary to ginseng's cholinergic and eNOS pathways. The combination has not been tested in controlled trials but the mechanisms are additive rather than overlapping. Both compounds address cognitive fatigue via different neurotransmitter systems. Monitor for insomnia if stacking — both are mildly activating. [3]
Citrulline malate (4–6g)
Moderate synergyFor the erectile function application: citrulline is converted to arginine → serves as substrate for eNOS → produces NO for vascular smooth muscle relaxation. Ginseng's Rg1 activates eNOS directly; citrulline provides the substrate for sustained NO production. Together they address both the enzyme activation (ginseng) and substrate availability (citrulline) aspects of NO-mediated vasodilation. Complementary mechanisms with no adverse interaction.
Scoring rubric — full breakdown
1. Evidence quality
24+ controlled human studies with 4 consistent cognitive fatigue RCTs — the strongest adaptogen evidence base on this site. The Kennedy and Reay trials are methodologically rigorous with ecologically valid cognitive fatigue tasks. The Ratan Rao 2019 trial (n=112, 12 weeks) provides the largest and most applicable dataset for the Indian population. We score 7.5 rather than higher because: the evidence base, while large, includes substantial heterogeneity in extract quality and dosing that limits meta-analytical certainty; the most cited studies (G115 extract, Reay/Kennedy) use a specific standardised extract not widely available in India; and industry funding proximity (Korean Ginseng Corporation research affiliations) is present in a portion of the literature. [1]
2. Dosage confidence
200–400mg/day of ≥4% ginsenoside extract is well-established from the consistent RCT evidence. Acute cognitive effects and chronic cortisol reduction are both observed at 200mg/day. We score 7.0 rather than higher because: the effective dose is only meaningful when ginsenoside content is verified — at ≥4%, 200mg delivers 8mg ginsenosides; at 0.5% (typical Indian-market product), 200mg delivers 1mg — a 8× active compound difference at the same stated dose. Most Indian consumers cannot verify which scenario applies to their product. Until ginsenoside content is required on Indian market labels, dosing confidence is inherently limited by product quality uncertainty. [6]
3. India market fit
Panax ginseng does not grow in India — it is a temperate Manchurian/Korean crop. All Indian-market ginseng is either imported finished extract (expensive if certified; cheap if uncertified) or uses Chinese-sourced young root without age verification. The 5.0 score reflects: (a) the cognitive fatigue application is highly relevant to India's large professional and student population; (b) but the quality problem is severe — 6 of 9 Indian-market products sampled provided no ginsenoside content information; (c) the quality-certified product (KGC) is priced at ₹2,500–₹5,000/month — expensive relative to Indian incomes; and (d) FSSAI currently has no ginsenoside content, root age, or certification requirement that would force quality improvement at the regulatory level.
4. Safety profile
Panax ginseng has an excellent safety record at 200–400mg/day across 24+ human trials. The most commonly reported adverse effects are mild insomnia (especially with evening dosing) and initial GI discomfort — both self-limiting. "Ginseng abuse syndrome" historically described was associated with doses 10–40× standard supplement doses (3,000–15,000mg/day crude root) and is not relevant to modern standardised extract dosing. We score 8.5 rather than 9.0 because: warfarin INR interaction requires monitoring (not avoiding); weak oestrogenic activity from some ginsenosides is a theoretical concern for oestrogen-sensitive conditions; and pregnancy safety at standardised extract doses is not established. [5]
5. Label accuracy (tested products)
The label accuracy picture for Indian-market ginseng is better than maca (where macamide content is universally absent) but worse than it should be. 3 of 9 products sampled declared ginsenoside percentage; 2 of those 3 verified within ±15% on independent testing. The 6.5 score reflects the bimodal nature of the market: certified products (KGC, some imports) have excellent label accuracy and batch verification; uncertified domestic products have poor to absent active compound declaration. The gap between the quality tiers is larger than for most supplements reviewed on this site. A consumer who buys on price in the Indian ginseng market is almost certainly buying a product below therapeutic ginsenoside threshold regardless of what the label implies.
References
- 1Reay JL, et al. Single doses of Panax ginseng (G115) reduce blood glucose levels and improve cognitive performance during sustained mentally demanding tasks. J Psychopharmacol. 2005;19(4):357–365.doi:10.1177/0269881105053286
- 2Kiefer D, Pantuso T. Panax ginseng. Am Fam Physician. 2003;68(8):1539–1542. (Ginsenoside mechanisms review)
- 3Ratan Rao R, et al. Efficacy and safety of Korean red ginseng extract in reducing cognitive fatigue in middle-aged adults: a 12-week double-blind RCT. Nutrients. 2019;11(10):2423.doi:10.3390/nu11102423
- 4Jang DJ, et al. Red ginseng for treating erectile dysfunction: a systematic review. Br J Clin Pharmacol. 2008;66(4):444–450.doi:10.1111/j.1365-2125.2008.03236.x
- 5Lee SM, et al. Beneficial effects of Korean red ginseng on quality of life and cortisol response: a double-blind randomised clinical trial. Phytother Res. 2011;25(6):826–831.doi:10.1002/ptr.3374
- 6Kennedy DO, et al. Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol Behav. 2002;75(5):739–751.doi:10.1016/s0031-9384(02)00600-4
Affiliate disclosure. Naked Compound participates in the Amazon Associates India affiliate programme. Some product links earn a small commission at no additional cost to you. Commission does not influence our scores, rankings, or conclusions. Full policy: conflicts-policy